- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation routing:
- Medicines Evaluation
- Rationale:
- Review of TA987
- Process:
- Cost Comparison Standard
- ID number:
- 6619
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- Bristol-Myers Squibb (lisocabtagene maraleucel)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer52
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Lymphoma Action
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- WMUK
- Professional groups
- Association of Cancer Physicians
- British Blood Transfusion Society
- British Geriatrics Society
- British Institute of Radiology (BIR)
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Cutaneous Lymphoma Group
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- AbbVie (epcoritamab)
- Accord Healthcare (carboplatin, cisplatin, cytarabine, gemcitabine)
- Advanz Pharma (dexamethasone)
- Amarox (cisplatin, oxaliplatin)
- AS Kalceks (dexamethasone, oxaliplatin)
- Aspen (dexamethasone)
- Aspire Pharma (dexamethasone)
- Baxter Healthcare (ifosfamide)
- Celltrion Healthcare UK (rituximab)
- Chemidex Pharma (dexamethasone)
- Dr. Reddy’s Laboratories (UK) (bendamustine, rituximab)
- Ennogen Healthcare International (dexamethasone)
- Gilead Sciences (axicabtagene ciloleucel)
- Glenmark Pharmaceuticals (dexamethasone)
- Hameln Pharma (dexamethasone)
- Hospira UK (carboplatin, cisplatin, cytarabine, dexamethasone, gemcitabine)
- Jazz Pharmaceuticals UK (cytarabine)
- KrKa UK (dexamethasone)
- Martindale Pharma (dexamethasone)
- Medac Pharma (epirubicin, oxaliplatin)
- Napp Pharmaceuticals (rituximab)
- Neon Healthcare (etoposide)
- Novartis Pharmaceuticals UK (dexamethasone)
- Panpharma UK (dexamethasone)
- Pfizer (cytarabine, epirubicin, methylprednisolone, rituximab)
- Rayner Pharmaceuticals (dexamethasone)
- Roche Products (rituximab, glofitamab, polatuzumab vedotin)
- Rosemont Pharmaceuticals (dexamethasone)
- Sandoz (cisplatin, rituximab)
- Seacross Phramaceuticals (bendamustine, epirubicin, oxaliplatin)
- Sun Pharmaceutical (gemcitabine, oxaliplatin)
- Swedish Orphan Biovitrum (loncastuximab tesirine)
- Synchrony Pharma (dexamethasone, gemcitabine)
- Thame Laboratories (dexamethasone)
- Thea Pharmaceuticals (dexamethasone)
- Wockhardt UK (dexamethasone)
- Zentiva (dexamethasone)
- General commentators
- All Wales Therapeutics & Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematology
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- Leukaemia UK
- Lymphoma Research Trust
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 December 2025 | In progress. Review of TA987 |
| 25 November 2025 | Invitation to participate |
| 26 September 2025 - 13 October 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 August 2025 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual